Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
VENTOLIN HFA (albuterol sulfate) is a metered-dose inhaler containing a short-acting beta-2 adrenergic agonist approved for treatment of bronchospasm and exercise-induced bronchospasm in patients 4 years and older. The drug works by stimulating beta-2 adrenergic receptors in bronchial smooth muscle, increasing cyclic AMP and causing rapid bronchodilation. Albuterol demonstrates onset of action within 5 minutes with peak effect at approximately 1 hour, making it a first-line rescue therapy in asthma management. It remains a foundational component of asthma treatment protocols globally.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Worked on VENTOLIN HFA at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$193M Medicare spend — this is a commercially significant brand
VENTOLIN HFA creation opportunities are primarily in brand management, respiratory disease specialists (MSLs), and primary care field teams focused on asthma management and patient adherence. Key skills include asthma pathophysiology, formulary navigation, generic competition strategy, and patient education on inhaler technique. Currently zero linked open positions are reported for this product, reflecting its mature market status and commoditized nature.